Xintela completes clinical study with XSTEM in knee osteoarthritis
Xintela’s clinical study with XSTEM in knee osteoarthritis has been completed with the last follow-up visit for the last patient. Xintela previously communicated positive interim results up to 18 months after treatment and now completed the collection of 24-months data for the highest dose level. The final results of the study are planned to be reported […]
Xintela AB changes Certified Adviser to Tapper Partners AB
Xintela AB announces today that the company is changing its Certified Adviser to Tapper Partners AB. Xintela AB has entered into an agreement with Tapper Partners AB regarding the role as Certified Adviser. Tapper Partners AB will assume the role of Certified Adviser on August 15, 2025. Until then, DNB Carnegie Investment Bank AB will […]
Xintela and EQGen Biomedical sign collaboration and license agreement for veterinarian stem cell products
Xintela and EQGen Biomedical Inc. (“EQGen”) have signed the definitive collaboration and license agreement, contemplated by their previously announced term sheet, for the development of Xintela’s equine stem cell product EQSTEM® and other animal stem cell products. EQGen gets global rights to Xintela’s stem cell technology for the treatment of veterinary musculoskeletal indications. Xintela and […]
Xintela decreases patient number in XSTEM clinical study in difficult-to-heal venous leg ulcers
Xintela has amended the study protocol in the clinical phase I/IIa study with XSTEM on patients with difficult-to-heal venous leg ulcers to complete the study earlier. The number of patients to be enrolled in the study has been reduced from 12 to 6. The primary goal of the study, to investigate safety and tolerability, will […]
Xintela’s stem cell product XSTEM shows safety and positive efficacy results in knee osteoarthritis clinical study
Xintela’s interim analysis of data from the knee osteoarthritis clinical study shows safety and positive efficacy results, 18 months after treatment with XSTEM. The results demonstrate statistically significant and clinically meaningful improvements in knee pain and knee function. In addition, the results of XSTEM treatment show an improvement in bone structure and also a trend […]
Xintela’s main owner Flerie undertakes to exercise warrants TO3 of approximately SEK 28 million and provides a bridge loan of SEK 9 million
Xintela AB (publ) (“Xintela” or the “Company”) today announces that the Company’s largest shareholder Flerie Invest AB, which holds approximately 55.5 percent of the number of shares and votes in the Company, has committed to exercise warrants of series TO3 of approximately SEK 28 million during the exercise period beginning on November 25, 2024. Flerie’s […]
Xintela presents new preclinical results of XSTEM treatment on would healing and skin regeneration at cell therapy conference
Xintela is presenting today new preclinical data with the company’s stem cell product XSTEM® for wound healing and skin regeneration at the International Society for Cell & Gene Therapy (ISCT) Europe 2024, in Gothenburg. The results are presented both as a poster and as an oral presentation. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected […]
Xintela signs agreement with Region Östergötland for GMP process development of cell therapy for burn patients
Xintela and Region Östergötland have signed an agreement where Xintela will develop and establish a GMP process to isolate and quality assure autologous (patient-own) skin cells for the treatment of burns. The agreement is worth SEK 3.6 million. The process will form the basis for an approval from the Medical Products Agency for the Burn […]
Xintela extends clinical study with XSTEM on knee osteoarthritis patients
Xintela has implemented a change to the clinical study protocol where the follow-up time for the patients at the highest dose level has been extended by 6 months to obtain additional efficacy data for XSTEM® 24 months after dosing. An interim analysis of study data up to 18 months post dosing for all dose levels […]
Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses
Xintela and EQGen Biomedical Inc. have signed a non-binding term sheet for a license agreement where EQGen gets global rights to Xintela’s equine stem cell product EQSTEM®. Xintela and EQGen Biomedical, a newly formed US company, will collaborate on clinical development and commercialization of EQSTEM, initially in USA for the treatment of joint diseases in […]
